| Expression pattern: |
UP |
| Associated gene: |
c-MYC, GLS1 |
| Associated microRNA: |
miR-33a-5p, miR-145-5p, miR-203 |
| Biological function: |
promotes colony formation, migration and tumorigenicity; sustains altered glutaminolysis and glycolysis/glutaminolytic fluxes; increases sensitivity to GLS1 inhibition when depleted |
| Molecular mechanism: |
ceRNA sponging of miR-33a-5p leading to increased c-MYC transcriptional activity and upregulation of GLS1 (glutaminase) expression; c-MYC binds GLS promoter |
| Biological pathway or process: |
glutaminolysis (promotes); glycolysis (promotes); proliferation (promotes); migration (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Cohort Study; Survival Analysis; Bioinformatics Analysis; Back-Splice Junction PCR / divergent primers PCR; Digital PCR analysis; RIP (RNA Immunoprecipitation); Nuclear-Cytoplasmic Fractionation; Transfection; Colony Formation Assay; Transwell Assay; RNA Pull-Down; ChIP / ChIP-seq; Western Blot; In Vivo Animal Model; CCK8 |
| Clinical significance: |
Basal like breast cancer patients with higher levels of circPVT1 exhibited shorter disease-free survival compared to those with lower expression. |
| Description: |
circPVT1 is up-regulated in breast cancer tissues and promotes oncogenic phenotypes and metabolic reprogramming. It predominantly localizes in the cytoplasm and sponges miR-33a-5p (also miR-145-5p and miR-203), thereby increasing c-MYC activity and transcriptional upregulation of GLS1 to enhance glutaminolysis and support tumor progression; circPVT1 depletion sensitizes cells and TNBC patient-derived organoids to GLS1 inhibitors. |
| Confidence score: |
0.8554 |